BioCentury | Aug 4, 2020
Politics, Policy & Law

China doubling size of centralized procurement program

...drug Livalo pitavastatin from Kowa Co. Ltd. and Alzheimer’s disease (AD) therapy Namenda memantine from Merz GmbH & Co. KGaA...
BioCentury | Mar 17, 2020
Product Development

March 16 Quick Takes: FDA raises efficacy questions for DBV allergy therapy; plus Novo, Provention, UCB, Pfizer-EMD Serono, Zai, AcelRx-Tetraphase, Medivir-Tan

...063) Bavencio, avelumab (MSB0010718C, PF-06834635, Anti-PD-L1) Xerava, eravacycline (TP-434, IV TP-434) teplizumab (MGA031, PRV-031) Viaskin Peanut (DBV-712) Novo Nordisk A/S UCB S.A. Merz GmbH & Co. KGaA Pfizer...
BioCentury | Aug 20, 2019
Company News

Management tracks: uniQure, Provention, Anaptys, FDA and more

...effective November. Bakker was VP medical for the Tagrisso osimertinib franchise at AstraZeneca plc (LSE:AZN;NYSE:AZN). Merz GmbH & Co. KGaA...
...Tuesday. Friedman was managing director at First Analysis Securities Corp. Jonathan Block, Associate Editor AnaptysBio Inc. Marker Therapeutics Inc. Merz GmbH & Co. KGaA Nordic...
BioCentury | Jan 3, 2019
Distillery Therapeutics

Cancer

...traumatic brain injury (TBI), Alzheimer's disease (AD) and Parkinson's disease (PD). Brickell Biotech Inc. and Merz GmbH & Co. KGaA...
BioCentury | Aug 10, 2018
Company News

Management tracks: Oncopeptides, Merz

...AB (Stockholm, Sweden) as well as Wilson Therapeutics AB, which Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) acquired. Merz GmbH & Co. KGaA...
BioCentury | Jun 23, 2017
Clinical News

Merz’s Xeomin meets in Phase III trial for PD-associated sialorrhea

...The Merz Neurosciences unit of Merz GmbH & Co. KGaA (Frankfurt, Germany) reported top-line data from the Phase III SIAXI...
...Merz markets the product to treat upper limb spasticity, cervical dystonia, blepharospasm and glabellar lines. Merz GmbH & Co. KGaA...
...in uSFR and GICS at 12 weeks Status: Phase III data Milestone: NA Julian Zhu Bocouture incobotulinumtoxinA NT 201 Xeomin Xeomin Cosmetic Merz GmbH & Co. KGaA International...
BioCentury | Dec 14, 2016
Company News

Management tracks

...William Humphries as EVP of dermatology. He was CEO of the North American business at Merz GmbH & Co. KGaA...
BioCentury | Oct 27, 2016
Distillery Therapeutics

Cancer

...bexarotene, an RXR agonist, to treat cutaneous T cell lymphoma (CTCL). Brickell Biotech Inc. and Merz GmbH & Co. KGaA...
BioCentury | Mar 31, 2016
Distillery Therapeutics

Therapeutics: Dehydrosqualene desaturase (CrtN)

...and/or heart. Next steps include testing the CrtN inhibitor in additional models of MRSA infection. Merz GmbH & Co. KGaA...
BioCentury | Feb 18, 2016
Distillery Therapeutics

Therapeutics: Muscarinic acetylcholine receptor M1 (CHRM1; HM1); glial fibrillary acidic protein (GFAP)

...and other CHRM1 inhibitors in mammalian models of Alexander disease. Shionogi & Co. Ltd. and Merz GmbH & Co. KGaA...
Items per page:
1 - 10 of 217
BioCentury | Aug 4, 2020
Politics, Policy & Law

China doubling size of centralized procurement program

...drug Livalo pitavastatin from Kowa Co. Ltd. and Alzheimer’s disease (AD) therapy Namenda memantine from Merz GmbH & Co. KGaA...
BioCentury | Mar 17, 2020
Product Development

March 16 Quick Takes: FDA raises efficacy questions for DBV allergy therapy; plus Novo, Provention, UCB, Pfizer-EMD Serono, Zai, AcelRx-Tetraphase, Medivir-Tan

...063) Bavencio, avelumab (MSB0010718C, PF-06834635, Anti-PD-L1) Xerava, eravacycline (TP-434, IV TP-434) teplizumab (MGA031, PRV-031) Viaskin Peanut (DBV-712) Novo Nordisk A/S UCB S.A. Merz GmbH & Co. KGaA Pfizer...
BioCentury | Aug 20, 2019
Company News

Management tracks: uniQure, Provention, Anaptys, FDA and more

...effective November. Bakker was VP medical for the Tagrisso osimertinib franchise at AstraZeneca plc (LSE:AZN;NYSE:AZN). Merz GmbH & Co. KGaA...
...Tuesday. Friedman was managing director at First Analysis Securities Corp. Jonathan Block, Associate Editor AnaptysBio Inc. Marker Therapeutics Inc. Merz GmbH & Co. KGaA Nordic...
BioCentury | Jan 3, 2019
Distillery Therapeutics

Cancer

...traumatic brain injury (TBI), Alzheimer's disease (AD) and Parkinson's disease (PD). Brickell Biotech Inc. and Merz GmbH & Co. KGaA...
BioCentury | Aug 10, 2018
Company News

Management tracks: Oncopeptides, Merz

...AB (Stockholm, Sweden) as well as Wilson Therapeutics AB, which Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) acquired. Merz GmbH & Co. KGaA...
BioCentury | Jun 23, 2017
Clinical News

Merz’s Xeomin meets in Phase III trial for PD-associated sialorrhea

...The Merz Neurosciences unit of Merz GmbH & Co. KGaA (Frankfurt, Germany) reported top-line data from the Phase III SIAXI...
...Merz markets the product to treat upper limb spasticity, cervical dystonia, blepharospasm and glabellar lines. Merz GmbH & Co. KGaA...
...in uSFR and GICS at 12 weeks Status: Phase III data Milestone: NA Julian Zhu Bocouture incobotulinumtoxinA NT 201 Xeomin Xeomin Cosmetic Merz GmbH & Co. KGaA International...
BioCentury | Dec 14, 2016
Company News

Management tracks

...William Humphries as EVP of dermatology. He was CEO of the North American business at Merz GmbH & Co. KGaA...
BioCentury | Oct 27, 2016
Distillery Therapeutics

Cancer

...bexarotene, an RXR agonist, to treat cutaneous T cell lymphoma (CTCL). Brickell Biotech Inc. and Merz GmbH & Co. KGaA...
BioCentury | Mar 31, 2016
Distillery Therapeutics

Therapeutics: Dehydrosqualene desaturase (CrtN)

...and/or heart. Next steps include testing the CrtN inhibitor in additional models of MRSA infection. Merz GmbH & Co. KGaA...
BioCentury | Feb 18, 2016
Distillery Therapeutics

Therapeutics: Muscarinic acetylcholine receptor M1 (CHRM1; HM1); glial fibrillary acidic protein (GFAP)

...and other CHRM1 inhibitors in mammalian models of Alexander disease. Shionogi & Co. Ltd. and Merz GmbH & Co. KGaA...
Items per page:
1 - 10 of 217